Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
Studies have shown that using Castle’s DecisionDx®-Melanoma test to help guide the care of patients with melanoma, the deadliest form of skin cancer, improves health outcomes1-5 Castle’s...
Source: marketscreener.com